Go Pro
NYSE:KVUE

Kenvue Q2 2026 Earnings Report

Kenvue logo
$17.22 0.00 (-0.02%)
Closing price 03:59 PM Eastern
Extended Trading
$17.20 -0.02 (-0.12%)
As of 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kenvue EPS Results

Actual EPS
$0.31
Consensus EPS
$0.32
Beat/Miss
Missed by -$0.01
One Year Ago EPS
$0.29

Kenvue Revenue Results

Actual Revenue
$3.96 billion
Expected Revenue
$3.97 billion
Beat/Miss
Missed by -$10.75 million
YoY Revenue Growth
+3.00%

Kenvue Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
9:30AM ET

Upcoming Earnings

Kenvue's Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Kenvue Earnings Headlines

Kenvue (KVUE) Stock Still Appears 41% Undervalued On Cash Flow
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
EU extends review of Kimberly-Clark’s $40B Kenvue deal
See More Kenvue Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kenvue? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kenvue and other key companies, straight to your email.

About Kenvue

Kenvue (NYSE:KVUE) (NYSE: KVUE) is a consumer health company that develops, markets and sells self-care, skin health and essential health products. Its portfolio includes over-the-counter medicines, allergy and cold remedies, pain-relief products, oral-care items, wound-care products, baby care products and beauty brands.

Kenvue’s principal brands include Tylenol, Motrin, Zyrtec, Benadryl, Neutrogena, Aveeno, Listerine, Johnson’s and BAND-AID. The company distributes its products through pharmacies, retailers, e-commerce channels, healthcare providers and other commercial outlets in markets around the world.

Kenvue was formed through the separation of Johnson & Johnson’s consumer health business and became an independent publicly traded company in 2023. The company is headquartered in Skillman, New Jersey, and serves consumers across a broad range of geographic markets. Its leadership is focused on expanding its established brand portfolio and developing consumer health products intended for everyday use.

View Kenvue Profile